Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma
Epcoritamab + Polatuzumab +RCHP
CD20+CD3 bispecific Ab
Unknown
I b/ II
Arm 3B
DLBCL (de novo or histologically transformed from follicular lymphoma or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease, inclusive of the Following the WHO 2016 classification and documented in pathology report: a.DLBCL, not otherwise specified (NOS) b.High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per World Health Organization (WHO) 2016 ("double-hit" or "triple-hit") Note: High-grade B-cell lymphomas NOS or other double-/triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible c.FL Grade 3B
Unknown
李佳玲
4620